Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06441266 · ClinicalTrials.gov registry record · NA

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

A NA study of Radiation Dermatitis, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT06441266 is a NA study of Radiation Dermatitis that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 47-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06441266, a NA study of Radiation Dermatitis, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to test the ability of a mobile device application (MyCap) to collect patient information about their radiation skin rash in patients with head and neck cancer being treated with radiation therapy.

Conditions Studied

Interventions

  • DRUG KeraStat cream
  • DEVICE M-PART Assessments via MyCap
  • OTHER Clinical Assessments
  • OTHER Feedback phone interview

Study Locations (1)

North Carolina

  • Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-05-08
Est. Completion 2027-08
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT06441266

The ClinicalTrials.gov registry entry for NCT06441266 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (66% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Radiation Dermatitis appearing as the primary indexed condition, and to 4 interventions - of which KeraStat cream is the first listed.

NCT06441266 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06441266 about?

NCT06441266 is a clinical study titled "M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis". The purpose of this research study is to test the ability of a mobile device application (MyCap) to collect patient information about their radiation skin rash in patients with head and neck cancer being treated with radiation therapy.

What is the current status of trial NCT06441266?

This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-05-08. Estimated completion is 2027-08.

What conditions does trial NCT06441266 study?

This clinical trial studies the following conditions: Radiation Dermatitis.

What interventions are being tested in trial NCT06441266?

The interventions under investigation include: KeraStat cream (DRUG), M-PART Assessments via MyCap (DEVICE), Clinical Assessments (OTHER), Feedback phone interview (OTHER).

Who is sponsoring clinical trial NCT06441266?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06441266 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Radiation Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.